Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Earnings Report 5.786 USD Q2 2025 Earnings Release 08/07/2025 Earnings Report 6.286 USD Q3 2025 Earnings Release 10/30/2025 Earnings Report 7.208 USD Q4 2025 Earnings Release 02/11/2026 Earnings ...

Recently, Eli Lilly (LLY) revealed that they saw some concerning indicators for their GLP-1 drug in December, which might have been the culprit behind them missing their Q4 revenue guidance by $400M.

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Darzalex, which treats multiple myeloma, has become the first Johnson & Johnson drug to ever top $3 billion in quarterly ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare ... For Mounjaro, the diabetes treatment, Q4 sales will total $3.5 billion -- well short of analyst estimates of $4.4 billion.

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...